Lupus

Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.

The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.

Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.

New data support the continued assessment of the investigative drug for adults with SLE.

The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.

Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.

With several targeted therapies demonstrating positive trial results in lupus nephritis, the treatment paradigm appears to be shifting.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

Resources that can help educate patients with lupus about their diagnosis and encourage them to take a more proactive role in self-care.

Types of tests used to evaluate patients for signs of lupus or disease progression.

More than 50% of patients with classified SLE at Washington University’s Lupus Clinic exhibit clinically meaningful and persistent depression and anxiety symptoms over time.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

Types of patient populations at higher risk for developing more severe forms of lupus.

Criteria used by rheumatologists to help classify lupus due to its heterogenous manifestation.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 18, 2021.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “SLE Update: Novel treatments, and how we assess them.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.

In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.

Chengappa Kavadichanda, MD, discusses his study, “Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network.”

Meningitis is the most frequent clinical syndrome in SLE patients with CNS infections. C. neoformans, M. tuberculosis and L. monocytogenes are the most common causative pathogens.

Stephen Balevic, MD, explains hydroxychloroquine PK and exposure-response in pregnancies with lupus and the importance of adhering to treatment both during pregnancy and postpartum.